27th Sep 2022
Celix Pharma announces the launch of Sitagliptin Tablets
Celix Pharma is pleased to announce the launch of Sitagliptin 25mg, 50mg and 100mg film-coated tablets on loss of exclusivity in the UK. All 3 strengths are available in blister packs of 28 tablets.
Sitagliptin belongs to a class of drugs called DPP4 inhibitors and is indicated for treatment of Type 2 diabetes, either as a monotherapy or in combination with metformin and/or a sulphonylurea. Sitagliptin works by increasing the amount of insulin that the body makes, which is the hormone that controls sugar levels in your blood(1).
Commenting on this launch, Subir Kohli, Co-founder & CEO said, “We are excited to launch another product for our retail pharmacy and wholesale customers. Sitagliptin is the largest of the DDP4 inhibitors in the UK and launch of a generic equivalent will offer substantial savings to the NHS, which spends over £100million on this drug(2)annually.”
Shantreddy, Co-founder & COO added, “Very pleased with another product launch on day 1, which again reinforces the focus Celix Pharma puts on execution”.
1 Source: NHS UK (https://www.nhs.uk/medicines/sitagliptin/about-sitagliptin/)
2 IQVIA data
About Celix Pharma Ltd
Celix Pharma is a London-based generic pharmaceutical company founded in 2020 with an overarching goal to bring high quality, affordable, generic medicines with a sustainable supply chain to the UK. Celix Pharma focuses on bridging gaps in the market by identifying product opportunities arising from complexities in development and/or manufacturing, addressing supply disruptions and future patent expiries. Celix Pharma is building a portfolio across both, primary-care and secondary-care, with a range of generics, branded generics, and hospital specialty products. Celix Pharma’s business model is built around creating a commercially-led, customer-focused organization supported with strategic partnerships in R&D and manufacturing.
For more information, visit www.celixpharma.com